Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Comparison between subtenon anaesthesia and peribulbar anaesthesia for phacoemulsification surgery

Poster Details

First Author: S.Sarkar INDIA

Co Author(s):    A. Pilania                    

Abstract Details


Evaluation of the safety , efficacy and outcome of subtenon anaesthesia with peribulbar anaesthesia in Phacoemulsification cataract surgery.


Chandraprabha Eye Hospital, Jorhat, Assam, India- 785001


This was a prospective randomized controlled study with 500 eyes of 420 patients between july 2017 to December 2017 who underwent phacoemulsification surgery. All the patients were randomly divided into 2 groups. Group A underwent phacoemulsification with subtenon aneasthesia and group B underwent phacoemulsification with peribulbar aneathesia. Pain during administration of anaesthesia, during surgery and 4 h after surgery was graded on a visual analogue pain scale and compared for both the techniques. Sub-conjuntival haemorrhage, chemosis, akinesia after administration of anaesthesia and positive pressure during surgery were also compared. Patients were followed up for 6 weeks postoperatively.


All the patients were followed up for 6 weeks. In subtenon group 202 out of 250 patients(80.8%)did not experienced any pain during administration of aneasthesia. Meanwhile in peribulbar group only 48 out of 250 patients (19.2%) did not received any pain during administration. There was no significant difference in pain during and 4 h after surgery. Subtenon group had slightly more sub-conjunctival haemorrhage. About 178 (71.2%) patients of the peribulbar group had absolute akinesia during surgery as compared to none (0%) in sub-tenon group.There was 1 case globe perforation during peribulbar administration.


Sub-tenon anaesthesia is safe and as effective as peribulbar anaesthesia and is more comfortable to the patient at the time of administration.

Financial Disclosure:


Back to Poster listing